Epidemiology of Mycoplasma genitalium and Trichomonas vaginalis in the Primary Health Care Setting in the Netherlands

  • Erlangga Yusuf*
  • , Kelly Mertens
  • , Nico Van Lisdonk
  • , Cindy Houwen
  • , Khoa T.D. Thai
  • *Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

12 Citations (Scopus)
84 Downloads (Pure)

Abstract

The aim of this paper is to describe the prevalence of Mycoplasma genitalium and Trichomonas vaginalis in patients who visited general practitioners in the Netherlands. Additionally, we describe the prevalence of M. genitalium resistance to azithromycin and moxifloxacin. We used data from 7,411 consecutive female patients who were screened for Chlamydia trachomatis, Neisseria gonorrhoeae, M. genitalium, and T. vaginalis and data from 5,732 consecutive male patients screened for C. trachomatis, N. gonorrhoeae, and M. genitalium. The prevalence of M. genitalium and T. vaginalis in female patients was 6.7% (95% CI: 6.2 to 7.4) and 1.9% (95%CI: 1.6 to 2.2%), respectively. M. genitalium prevalence in male patients was 3.7% (3.3 to 4.3). M. genitalium co-occurred with C. trachomatis in 1.4% (0.3 to 0.6%) of female and in 0.7% (0.5 to 0.9) of male patients. Macrolide resistance gene mutations and fluoroquinolone resistance gene mutations were detected in 73.8% and 9.9%, respectively. We concluded that M.genitalium is relatively infrequently found in a large general practitioner population in the Netherlands. It can co-occur with C. trachomatis, and is often resistant to azithromycin. Therefore, when treating sexually transmitted infections, these prevalence and resistance data should be taken into account.

Original languageEnglish
Article numbere79
JournalEpidemiology and Infection
Volume151
Early online date5 May 2023
DOIs
Publication statusPublished - 5 May 2023

Bibliographical note

Publisher Copyright:
© The Author(s), 2023. Published by Cambridge University Press.

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Fingerprint

Dive into the research topics of 'Epidemiology of Mycoplasma genitalium and Trichomonas vaginalis in the Primary Health Care Setting in the Netherlands'. Together they form a unique fingerprint.

Cite this